转录因子YBX1调控HCC的耐药和肿瘤进展。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-07-25 DOI:10.1016/j.drudis.2025.104439

Dennis Kwabiah , Veerababu Nagati , Manish K. Tripathi

{"title":"转录因子YBX1调控HCC的耐药和肿瘤进展。","authors":"Dennis Kwabiah , Veerababu Nagati , Manish K. Tripathi","doi":"10.1016/j.drudis.2025.104439","DOIUrl":null,"url":null,"abstract":"<div><div>Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths. Transcription factors (TFs), which control vital cellular processes, also play a crucial role in cancer development and resistance. In hepatocellular carcinoma (HCC), resistance to sorafenib, a primary targeted therapy, significantly impairs treatment effectiveness and worsens patient outcomes. Among TFs, Y-box binding protein 1 (YBX1) has been recognized as a regulator of aggressive cancer traits in colorectal and breast cancers. However, its role in HCC and sorafenib resistance remains unclear. This review examines YBX1’s role in HCC progression and drug resistance, its underlying molecular mechanisms, and its potential as a biomarker and therapeutic target for overcoming sorafenib resistance.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 9","pages":"Article 104439"},"PeriodicalIF":7.5000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC\",\"authors\":\"Dennis Kwabiah , Veerababu Nagati , Manish K. Tripathi\",\"doi\":\"10.1016/j.drudis.2025.104439\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths. Transcription factors (TFs), which control vital cellular processes, also play a crucial role in cancer development and resistance. In hepatocellular carcinoma (HCC), resistance to sorafenib, a primary targeted therapy, significantly impairs treatment effectiveness and worsens patient outcomes. Among TFs, Y-box binding protein 1 (YBX1) has been recognized as a regulator of aggressive cancer traits in colorectal and breast cancers. However, its role in HCC and sorafenib resistance remains unclear. This review examines YBX1’s role in HCC progression and drug resistance, its underlying molecular mechanisms, and its potential as a biomarker and therapeutic target for overcoming sorafenib resistance.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 9\",\"pages\":\"Article 104439\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001527\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001527","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

耐药性仍然是癌症治疗中的一个重大挑战，全球90%以上的癌症相关死亡是由耐药性造成的。转录因子（TFs）控制着重要的细胞过程，在癌症的发展和耐药性中也起着至关重要的作用。在肝细胞癌（HCC）中，对主要靶向治疗索拉非尼（sorafenib）的耐药性会显著损害治疗效果并恶化患者预后。在tf中，Y-box结合蛋白1 （YBX1）已被认为是结直肠癌和乳腺癌侵袭性癌症特征的调节因子。然而，其在HCC和索拉非尼耐药中的作用尚不清楚。本文综述了YBX1在HCC进展和耐药中的作用，其潜在的分子机制，以及其作为克服索拉非尼耐药的生物标志物和治疗靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC

查看原文本刊更多论文

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC

Drug resistance continues to be a significant challenge in cancer treatment, responsible for over 90% of worldwide cancer-related deaths. Transcription factors (TFs), which control vital cellular processes, also play a crucial role in cancer development and resistance. In hepatocellular carcinoma (HCC), resistance to sorafenib, a primary targeted therapy, significantly impairs treatment effectiveness and worsens patient outcomes. Among TFs, Y-box binding protein 1 (YBX1) has been recognized as a regulator of aggressive cancer traits in colorectal and breast cancers. However, its role in HCC and sorafenib resistance remains unclear. This review examines YBX1’s role in HCC progression and drug resistance, its underlying molecular mechanisms, and its potential as a biomarker and therapeutic target for overcoming sorafenib resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.